Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia
Phase 1
- Conditions
- Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05203055
- Locations
- 🇨🇳
Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, China
Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery
Not Applicable
- Conditions
- Esophageal Squamous Cell Carcinomas
- Interventions
- Radiation: radiotherapy
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04741490
- Locations
- 🇨🇳
Fuzhou General Hospital, Fuzhou, Fujian, China
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Phase 3
- Conditions
- Lung NeoplasmSmall Cell Lung CancerPD-1 Inhibitors
- Interventions
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT04490421
- Locations
- 🇨🇳
The 900th Hospital of Joint Logistic Support Force, Fuzhou, Fujian, China
Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
Early Phase 1
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04371601
- Locations
- 🇨🇳
Fuzhou General Hospital, Fuzhou, Fujian, China
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Phase 2
- Conditions
- Breast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast CancerBreast DiseasesHormone Receptor Positive Tumor
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT04088110
- Locations
- 🇨🇳
Fuzhou general hospital, Fuzhou, Fujian, China
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 92
- Registration Number
- NCT04015661
- Locations
- 🇨🇳
No. 156, North Road, Xierhuan Road, Fuzhou, Fujian, China
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- Drug: Temozolomide（TMZ）
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03567135
- Locations
- 🇨🇳
Fuzhou General Hospital, Fuzhou, Fujian, China
The Plasma Diafiltration Therapy of Hepatic Failure
Not Applicable
- Conditions
- Hepatic FailurePlasma Exchange
- Interventions
- Procedure: conventional PDF treatment groupProcedure: simple plasma exchangeProcedure: less plasma PDF treatment group
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03560414
- Locations
- 🇨🇳
Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, China
Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03516006
Mesenchymal Stem Cells in Central Nervous System injury2017
Phase 1
- Conditions
- Central Nervous System Injury
- Interventions
- Drug: UCMSCCDrug: conventional treatment
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03291366
© Copyright 2025. All Rights Reserved by MedPath